RxDoctor Payments Data

Mark Barettella, MD

Interventional Cardiology · Daytona Beach, FLNPI 1720040488

Payments from drug & device makers

$133,603in general payments, 2019–2025

Across 134 payments — averaging $997.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$73K
  • Boehringer Ingelheim International GmbH$32K
  • Sanofi$16K
  • AstraZeneca$12K
  • Abbott$538
  • Boehringer Ingelheim Pharma GmbH & Co.kg$508
  • plus $251 from 7 others

What the payments were for

  • Food & beverage$789100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$133,603 in reported general payments places this provider in the 85th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$296,425
Medicare patients
550
Services billed
5,608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$275,110
XareltoRivaroxaban127$163,421
EntrestoSacubitril/Valsartan49$47,013
Repatha SureclickEvolocumab29$38,270
Praluent PenAlirocumab25$22,480
VascepaIcosapent Ethyl16$8,021
Diltiazem 24hr Er (Cd)Diltiazem Hcl150$6,042
Metoprolol Succinate281$5,754
Atorvastatin Calcium212$3,376
Rosuvastatin Calcium186$3,221
Losartan Potassium231$3,075
Ezetimibe102$2,797
Carvedilol169$2,615
Potassium Chloride99$2,193
Amlodipine Besylate269$1,929

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$13$163,421127 claims
NovartisEntresto$35$47,01349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →